DDInter293 DDInter1676
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Carbamazepine {u} (Compound) resembles {v} (Compound) Magnesium salicylate
Carbamazepine {u} (Compound) resembles {v} (Compound) Modafinil
Carbamazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methdilazine
Carbamazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Carbamazepine {u} (Compound) treats {v} (Disease) epilepsy syndrome
Carbamazepine {u} (Compound) binds {v} (Gene) SCN9A
Carbamazepine {u} (Compound) upregulates {v} (Gene) PLCB3
Carbamazepine {u} (Compound) palliates {v} (Disease) bipolar disorder
Carbamazepine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 1A2 Inducers
Carbamazepine {u} (Compound) downregulates {v} (Gene) TIMM9
Carbamazepine (Compound) resembles Magnesium salicylate (Compound)
Carbamazepine (Compound) resembles Modafinil (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Carbamazepine (Compound) treats epilepsy syndrome (Disease)
Carbamazepine (Compound) binds SCN9A (Gene)
Carbamazepine (Compound) upregulates PLCB3 (Gene)
Carbamazepine (Compound) palliates bipolar disorder (Disease)
Carbamazepine (Compound) is included by Cytochrome P450 1A2 Inducers (Pharmacologic Class)
Carbamazepine (Compound) downregulates TIMM9 (Gene)